Alternative Strategy to Administer Antibody-Based Immunotherapy to Treat Bladder Cancer

by Shirley Johanna on  December 10, 2016 at 4:15 PM Cancer News
RSS Email Print This Page Comment bookmark
Font : A-A+

Cancer treatments can result in adverse side-effects. An alternative way to administer antibody-based immunotherapy without causing side effects has been found by researchers at the Uppsala University.
Alternative Strategy to Administer Antibody-Based Immunotherapy to Treat Bladder Cancer
Alternative Strategy to Administer Antibody-Based Immunotherapy to Treat Bladder Cancer

In antibody-based immunotherapy drugs are used to stimulate the body's own immune cells to attack and destroy the tumor cells. This method is presently used to treat certain types of metastasized cancer, such as melanoma and bladder cancer. However, a disadvantage of the therapy is that the drug is injected into the blood, which will lead to an exposure of the whole body and thereby possible adverse events.

Show Full Article

An alternative strategy would be to administer the drug directly in or close to the tumor, provided that this still leads to the desired immune cell stimulation. In the present study a group of researchers, led by Sara Mangsbo at Department of Immunology, Genetics and Pathology, IGP, had demonstrated that a local immune activation in the tumor area had the same tumor inhibiting capacity as when the drug was delivered in the blood.

'We found that the therapy that we tested in a model system of bladder cancer could stimulate the immune cells to find and attack the cancer cells, even if it was administered locally. These results are very promising since they indicate that it's not necessary to activate the body's whole immune system, but only the one that is relevant in the tumor. This way adverse events caused by the drug can be reduced,' says Sara Mangsbo.

In the study immune activation was achieved by administering blocking antibodies close to the tumor. The results complement the researcher's previous findings where they found that a direct immune stimulatory antibody had superior anti-tumor capacity when used locally at the tumor, as compared to after injection into the blood.

The hope is also that the immune cells, not the drug itself, can find potential metastases and eliminate them. To understand if and how this is happening, further research is required. The present results are based on studies in mice and to determine if drug administration to the tumor results in fewer adverse events in patients, as compared to injections into the blood stream, clinical studies are also needed.

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Recommended Reading

More News on:

Cancer and Homeopathy Immunisation Vesico-Ureteric Reflux Causing UTI in Children Enuresis/Bedwetting Cancer Facts Cancer Tattoos A Body Art Interstitial Cystitis Bladder Cancer Dealing with Pollen Allergy 

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive